Center for Connected Medicine at UPMC Finds EHR Integration Gap Is Defining Hurdle for Precision Medicine Scale

Why It Matters

Deep EHR integration determines whether precision‑medicine investments translate into measurable patient outcomes, influencing cost‑effectiveness and competitive advantage for health systems.

Key Takeaways

• 75% of health systems now have dedicated precision‑medicine units.
• Deep EHR integration, not just PDFs, drives actionable genomic care.
• Epic’s genomics modules enable discrete data and drug‑gene alerts.
• Governance shifting from permissions to execution for consistent practice.
• AI overlays accelerate interpretation and reduce clinician burden.

Pulse Analysis

Precision medicine has moved from experimental niche to a core service in most U.S. health systems. The Center for Connected Medicine at UPMC, with KLAS Research and the Institute for Precision Medicine, surveyed 21 leaders and found that 75 % now operate formal precision‑medicine units, up from 31 % in 2020. Pharmacogenomics adoption rose from 55 % to 90 %, while oncology, behavioral health and maternal‑fetal programs anchor new portfolios. This maturity shift masks a deeper operational divide: only organizations that embed genetic results as discrete, searchable data within the electronic health record are seeing measurable clinical impact.

Basic PDF or scanned‑image uploads no longer suffice. Systems using Epic’s genomics modules can order tests electronically and receive results in structured fields, enabling in‑line drug‑gene alerts and hard stops at prescribing. Achieving that depth requires coordinated data‑engineering, lab‑IT interfaces, and robust governance. About 60 % of respondents have appointed a dedicated precision‑medicine leader, and the trend is shifting toward execution‑focused governance that standardizes practice across sites. Multi‑lab exchanges add complexity, demanding real‑time vendor interfaces and variant reconciliation to keep data consistent.

Artificial intelligence is emerging as the next catalyst, overlaying decision‑support tools that triage variants, suggest therapies, and automate documentation. CIOs and CMIOs must align AI investments with genomic infrastructure while tackling the two most‑cited barriers: cost/reimbursement and clinician education. Pairing financial counseling with targeted training accelerates adoption and mitigates budgetary risk. For health systems aiming to scale, the operational scorecard should prioritize integration depth, execution‑oriented governance, and AI‑enabled analytics—elements that together turn raw genomic data into actionable bedside intelligence.